Physician profile
Kenneth Adam Arney
NPI 1801058557
$654.20
in general payments reported to CMS, 2019-2025
13 companies · $16.67 in 2025
The $16.67 reported for 2025 was less than what a typical Hospitalist provider received nationally (typical 2025 total: $85.87).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $142 · 2020: $22.18 · 2021: $27.33 · 2022: $105 · 2023: $151 · 2024: $191 · 2025: $16.67.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $358.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $358.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $106.41 | 2019-2024 | Xarelto, Spravato |
| Pfizer INC. | $93.99 | 2019-2024 | |
| Gilead Sciences, INC. | $69.80 | 2022-2024 | Veklury |
| Astrazeneca Pharmaceuticals LP | $63.12 | 2019-2023 | |
| Inari Medical, INC. | $61.59 | 2023-2024 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Mylan Specialty L.P. | $53.70 | 2020-2022 | |
| Melinta Therapeutics, LLC | $49.74 | 2019-2023 | Vabomere, Kimyrsa |
| Merck Sharp & Dohme LLC | $37.83 | 2022-2024 | Recarbrio, Dificid, Zerbaxa |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $36.67 | 2024-2025 | Lifevest |
| Ferring Pharmaceuticals INC. | $25.40 | 2024 | Rebyota |
| Boehringer Ingelheim Pharmaceuticals, INC. | $24.54 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $17.59 | 2019 | |
| Novartis Pharmaceuticals Corporation | $13.82 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kenneth Arney listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.